Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Endocrine Carcinoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Endocrine Carcinoma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 3 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      8 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01578239 · Source cited / selected · Scope: narrower

      A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT02487095 · Registry condition search · Scope: narrower

      Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

      6 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT03037385 · Source cited / selected · Scope: narrower

      Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

      6 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT03690388 · Source cited / selected · Scope: narrower

      A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Fact

      2 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT04514484 · Registry condition search · Scope: narrower

      Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT04579679 · Registry condition search · Scope: narrower

      Open-Label Surufatinib in European Patients With NET

      6 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT05022667 · Registry condition search · Scope: narrower

      Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT05152927 · Registry condition search · Scope: narrower

      Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-endocrine-carcinoma
        binding id
        ncit-C215715
        source collection
        ncit-concept
        source key
        C215715
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice